Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients

Table 1

Clinical information of all patients included in this study of microRNAs is given in the table. In the discovery set, samples collected from patients with long PFS and short PFS are selected from the upper and lower quartile of PFS, respectively. Samples in the validation set are recognized with less variation in survival time.

	⁢Discovery set				Validation set
	Bevacizumab long PFS	Standard chemotherapy long PFS	Bevacizumab short PFS	Standard chemotherapy short PFS	Bevacizumab	Standard chemotherapy
Number of samples
Age (average)	56.4	57.1	56.6	59.8	53.8	58.1
Histology
Serous	16	17	11	14	49	30
Mucinous	0	0	0	2	0	0
Endometrioid	1	3	0	2	2	4
Clear cell	3	4	4	2	10	4
Mixed	4	2	1	1	10	3
Other	1	0	0	3	2	2
FIGO
IA/IB/IC	4	5	0	0	5	3
IIA/IIB/IIC	7	7	2	0	6	4
IIIA/IIIB/IIIC	13	14	10	18	51	32
IV	1	0	4	6	11	4
Grade
1	2	1	0	0	5	2
2	2	4	1	5	11	6
3	19	21	15	17	57	34
Unknown	2	0	0	2		1
PFS median (months)	28.8	29.4	8.1	7.2	18	12.9
Residual disease
Inoperable	0	0	1	3	1	2
Residual > 1 cm	3	4	6	12	24	17
Residual ≤ 1 cm	5	2	6	5	20	6
Residual 0 cm	17	20	3	3	28	18